The role of mitogen-activated ERK-kinase inhibitors in lung cancer therapy.

Abstract excerpt

The Ras-Raf-MAPK pathway has been implicated in lung carcinogenesis and, potentially, the maintenance of the malignant phenotype in these tumors. Mutations in ras and B-raf genes have been described in lung cancer, representing one of the few examples of tandem mutations in a signaling cascade. As a result, numerous approaches to inhibiting this pathway in lung cancer have been explored in the past decade. The...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Benzamides
• Share to Carcinoma, Non-Small-Cell Lung
• Share to Enzyme Inhibitors